High CD90 Expression is A Predictor of Axillary Nodal Metastasis in Breast Carcinoma
Abstract
Background: Metastasis is the most common cause of death in breast cancer and nodal metastasis is one of the most important predictive factors for distance metastasis. One of the intrinsic properties of cancer cells is that they resemble stem cells which are capable of self-renewal, resistance to chemotherapy and radiation, and metastasis. CD90 is a stem cell marker found in several malignancies, including breast carcinoma. The objective of this study was to prove that CD90 can predict the occurrence of axillary nodal metastasis in breast carcinoma.
Methods: The study design was a case-control study. The subjects of this study were breast cancer patients at Prof. Dr. I. G. N. G. Ngoerah Hospital who underwent mastectomy and axillary lymphadenectomy in the year 2019. CD90 immunohistochemistry was performed and its association with metastasis, along with various clinicopathological markers, was assessed with chi-square and logistic regression tests with a significance level determined at α=0.05.
Results: There were 25 cases of breast carcinoma with axillary nodal metastasis and 25 cases without metastasis. There was a significant relationship between high CD90 expression and the occurrence of nodal metastasis (p=0.010). There was no relationship between patient age, histologic grade, histologic subtype, molecular subtype, and T-stage with axillary nodal metastasis. Breast carcinoma patients with high CD90 expression have a 7.25 times higher nodal metastasis risk compared to patients with low CD90 expression.
Conclusion: High CD90 expression could predict axillary nodal metastasis in breast carcinoma.
Keywords
DOI: 10.33371/ijoc.v18i2.1085
Article Metrics
Abstract View: 241, 
PDF Download: 120
References
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49.
Paskarani P, Sriwidyani N, Kurniasari N, et al. The Burden of Cancer in Bali: An Epidemiology Report 2017-2019. Int J Med Rev Case Reports. 2022;6(0):1.
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48.
Medeiros B, Allan AL. Molecular mechanisms of breast cancer metastasis to the lung: Clinical and experimental perspectives. Int J Mol Sci. 2019;20(9).
Stanisławek A. Breast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies- An Updated Review. 2021;1–30.
Ali B, Mubarik F, Zahid N, Sattar AK. Clinicopathologic Features Predictive of Distant Metastasis in Patients Diagnosed With Invasive Breast Cancer. JCO Glob Oncol. 2020;(6):1346–51.
Qiu Y, Wang L, Zhong X, et al. A multiple breast cancer stem cell model to predict recurrence of T1-3, N0 breast cancer. BMC Cancer. 2019;19(1):729.
Shan NL, Shin Y, Yang G, et al. Breast cancer stem cells: A review of their characteristics and the agents that affect them. Mol Carcinog. 2021 Feb;60(2):73-100.
Lu H, Clauser KR, Tam WL, et al. A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages. Nat Cell Biol. 2014 Nov;16(11):1105-17.
Yoshihara E, Smeets A, Laenen A, et al. Predictors of axillary lymph node metastases in early breast cancer and their applicability in clinical practice. Breast. 2013;22(3):357–61.
Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011;144(5):646–74.
Hanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022;12(1):31–46.
Smigiel JM, Taylor SE, Bryson BL, et al. Cellular plasticity and metastasis in breast cancer: a pre- and post-malignant problem. J Cancer Metastasis Treat. 2019;2019(June).
Kumar V, Abbas AK, Aster JC. Robbins Basic Pathology. 10th ed. Philadelphia: Elservier; 2018.
Sauzay C, Voutetakis K, Chatziioannou A, et al. CD90/Thy-1, a Cancer-Associated Cell Surface Signaling Molecule. Front Cell Dev Biol. 2019 Apr 26;7:66.
Fico F, Bousquenaud M, Rüegg C, Santamaria-Martínez A. Breast Cancer Stem Cells with Tumor- versus Metastasis-Initiating Capacities Are Modulated by TGFBR1 Inhibition. Stem Cell Reports. 2019;13(1):1–9.
Maia Lobba AR, Oliveira Carreira AC, Dutra Cerqueira OL, et al. High CD90 (THY-1) expression positively correlates with cell transformation and worse prognosis in basal-like breast cancer tumors. PLoS One. 2018;13(6):1–21.
Redig AJ, McAllister SS. Breast cancer as a systemic disease: a view of metastasis. J Intern Med. 2013 Aug;274(2):113-26.
Yamashita T, Kaneko S. Liver cancer stem cells: Recent progress in basic and clinical research. Regen Ther. 2021;17:34–7.
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Email this article 
